On October 3, 2024, the Food and Drug Administration sanctioned nivolumab (Opdivo, Bristol Myers Squibb Company) in conjunction with platinum-doublet chemotherapy as neoadjuvant therapy, succeeded b...
platinum-based-chemotherapy
On September 17, 2024, the Food and Drug Administration authorized pembrolizumab (Keytruda, Merck) in conjunction with pemetrexed and platinum-based chemotherapy as the initial treatment for unresec...
platinum-based-chemotherapy
Feb 2023: For stage IB (T2a 4 cm), stage II, or stage IIIA non-small cell lung cancer, the Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) as adjuvant therapy after resect...
platinum-based-chemotherapy
Squamous Neck Cancer with Occult Primary Treatment
Squamous neck cancer with occult primary (SNCOP) is an unusual but difficult disease in which cancerous squamous cells in the neck lymph nodes have ...
platinum-based-chemotherapy